Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

In their places are projected to be Novo Nordisk's (NVO) type 2 diabetes med Ozempic (semaglutide) and Regeneron Pharmaceuticals (NASDAQ:REGN)/Sanofi's (SNY) Dupixent (dupilumab), used for ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so far this year ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sales of Dupixent (dupilumab) rocketed 43% to €1.96 billion ($2 billion) – ahead of analyst expectations – driven by buoyant demand in its atopic dermatitis and severe asthma indications ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The use of Dupixent in AD has set a high benchmark for ... which is currently in four Phase III clinical trials (COAST 1, NCT06130566; COAST 2, NCT06181435; SHORE, NCT06224348; AQUA, NCT06241118).

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Dupixent remains a top growth driver ... Analysts see Altuviiio bringing in €2.3 billion in peak annual sales. Sanofi doesn't have many patent cliffs to worry about. Lantus now competes with ...